| Upregulation of integrin β4 promotes epithelial–mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma Y Masugi, K Yamazaki, K Emoto, K Effendi, H Tsujikawa, M Kitago, ... Laboratory investigation 95 (3), 308-319, 2015 | 154 | 2015 |
| OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma A Ueno, Y Masugi, K Yamazaki, M Komuta, K Effendi, Y Tanami, ... Journal of hepatology 61 (5), 1080-1087, 2014 | 132 | 2014 |
| Upregulated SMAD3 promotes epithelial–mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma K Yamazaki, Y Masugi, K Effendi, H Tsujikawa, N Hiraoka, M Kitago, ... Laboratory investigation 94 (6), 683-691, 2014 | 84 | 2014 |
| Bmi‐1 gene is upregulated in early‐stage hepatocellular carcinoma and correlates with ATP‐binding cassette transporter B1 expression K Effendi, T Mori, M Komuta, Y Masugi, W Du, M Sakamoto Cancer science 101 (3), 666-672, 2010 | 82 | 2010 |
| Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis T Mamiya, K Yamazaki, Y Masugi, T Mori, K Effendi, W Du, T Hibi, ... Laboratory investigation 90 (9), 1339-1345, 2010 | 75 | 2010 |
| Identification by differential tissue proteome analysis of talin-1 as a novel molecular marker of progression of hepatocellular carcinoma H Kanamori, T Kawakami, K Effendi, K Yamazaki, T Mori, H Ebinuma, ... Oncology 80 (5-6), 406-415, 2011 | 69 | 2011 |
| Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma K Emoto, Y Masugi, K Yamazaki, K Effendi, H Tsujikawa, M Tanabe, ... Human pathology 45 (4), 817-825, 2014 | 61 | 2014 |
| Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma M Sakamoto, T Mori, Y Masugi, K Effendi, I Rie, W Du Intervirology 51 (Suppl. 1), 42-45, 2008 | 58 | 2008 |
| Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease Y Masugi, T Abe, H Tsujikawa, K Effendi, A Hashiguchi, M Abe, Y Imai, ... Hepatology communications 2 (1), 58-68, 2018 | 57 | 2018 |
| Molecular diagnosis of multistage hepatocarcinogenesis M Sakamoto, K Effendi, Y Masugi Japanese journal of clinical oncology 40 (9), 891-896, 2010 | 53 | 2010 |
| Leucine-rich repeat-containing G protein-coupled receptor 5 regulates epithelial cell phenotype and survival of hepatocellular carcinoma cells M Fukuma, K Tanese, K Effendi, K Yamazaki, Y Masugi, M Suda, ... Experimental cell research 319 (3), 113-121, 2013 | 52 | 2013 |
| Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments Y Kurebayashi, K Matsuda, A Ueno, H Tsujikawa, K Yamazaki, Y Masugi, ... Hepatology 75 (5), 1139-1153, 2022 | 50 | 2022 |
| Molecular pathology in early hepatocarcinogenesis K Effendi, M Sakamoto Oncology 78 (2), 157-160, 2010 | 40 | 2010 |
| Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease M Sakamoto, H Tsujikawa, K Effendi, H Ojima, K Harada, Y Zen, F Kondo, ... Pathology international 67 (1), 1-7, 2017 | 32 | 2017 |
| Involvement of hepatocellular carcinoma biomarker, cyclase-associated protein 2 in zebrafish body development and cancer progression K Effendi, K Yamazaki, T Mori, Y Masugi, S Makino, M Sakamoto Experimental cell research 319 (1), 35-44, 2013 | 29 | 2013 |
| Overexpression of adenylate cyclase‐associated protein 2 is a novel prognostic marker in malignant melanoma Y Masugi, K Tanese, K Emoto, K Yamazaki, K Effendi, T Funakoshi, ... Pathology international 65 (12), 627-634, 2015 | 21 | 2015 |
| Biomarkers and personalized sorafenib therapy M Kudo Liver cancer 3 (3-4), 399, 2014 | 21 | 2014 |
| Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) represents a typical Wnt/β-catenin pathway-activated hepatocellular carcinoma K Effendi, K Yamazaki, M Fukuma, M Sakamoto Liver Cancer 3 (3-4), 451-457, 2014 | 20 | 2014 |
| Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma WT Kwa, K Effendi, K Yamazaki, N Kubota, M Hatano, A Ueno, Y Masugi, ... Pathology international 70 (9), 624-632, 2020 | 18 | 2020 |
| Pathological findings of NASH and NAFLD: for guidebook of NASH and NAFLD, 2015: The Japan society of hepatology Working Group*, ... Hepatology Research 47 (1), 3-10, 2017 | 13* | 2017 |
